title: Ibrutinib in very elderly patients with relapsed/refractory chronic lymphocytic leukemia: A real-world experience of 71 patients treated in France: A study from the French Innovative Leukemia Organization (FILO) group.
authors.affiliation: Department of hematology, Centre Léon Bérard, CLCC, Lyon, France.
authors.forename: Anne-Sophie
authors.identifier: 0000-0002-4256-8126
authors.initials: AS
authors.lastname: Michallet
authors.affiliation: Brabois hospital, Department of hematology, CHU Nancy, Vandoeuvre les Nancy, France.
authors.forename: Arnaud
authors.initials: A
authors.lastname: Campidelli
authors.affiliation: Department of hematology, Hospices Civils de Lyon, Lyon, France.
authors.forename: Helene
authors.initials: H
authors.lastname: Lequeu
authors.affiliation: Haut Levêque hospital, Deaptment of hematology, CHU Bordeaux, Bordeaux, France.
authors.forename: Marie-Sarah
authors.initials: MS
authors.lastname: Dilhuydy
authors.affiliation: Estaing hospital, CHU Clermont Ferrand, Clermont Ferrand, France.
authors.forename: Olivier
authors.initials: O
authors.lastname: Tournilhac
authors.affiliation: Civil hospital, CHU Strasbourg, Strasbourg, France.
authors.forename: Luc-Matthieu
authors.initials: LM
authors.lastname: Fornecker
authors.affiliation: Henri Mondor hospital, lymphoid unit, APHP, Paris, France.
authors.forename: Jehan
authors.initials: J
authors.lastname: Dupuis
authors.affiliation: Avicenne Hospital, APHP, Paris, France.
authors.forename: Florence
authors.initials: F
authors.lastname: Cymbalista
authors.affiliation: Department of hematology, CHU Rennes, Rennes, France.
authors.forename: Sophie
authors.initials: S
authors.lastname: De Guibert
authors.affiliation: Robert Debré hospital, CHU Reims, Reims, France.
authors.forename: Alain
authors.initials: A
authors.lastname: Delmer
authors.affiliation: Hematology institute Basse Normandie, CHU Caen, Caen, France.
authors.forename: Jean-Pierre
authors.initials: JP
authors.lastname: Vilque
authors.affiliation: Department of hematology, Institut Gustave Roussy, Paris, France.
authors.forename: David
authors.initials: D
authors.lastname: Ghez
authors.affiliation: UPMC University Paris 6 GRC11 GRECHY, APHP Hôpital Pitié Salpétrière, Paris, France.
authors.forename: Veronique
authors.initials: V
authors.lastname: Leblond
authors.affiliation: Department of biosatistics, Hospices Civils de Lyon, Lyon, France.
authors.forename: Fabien
authors.initials: F
authors.lastname: Subtil
authors.affiliation: Brabois hospital, Department of hematology, CHU Nancy, Vandoeuvre les Nancy, France.
authors.forename: Pierre
authors.initials: P
authors.lastname: Feugier
authors.affiliation: IUCT Oncopole, Toulouse, France.
authors.forename: Loic
authors.identifier: 0000-0001-8478-5623
authors.initials: L
authors.lastname: Ysebaert
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000139:chemically induced; D004305:Dose-Response Relationship, Drug; D005260:Female; D005602:France / Q000453:epidemiology; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006402:Hematologic Diseases / Q000139:chemically induced; D006801:Humans; D007239:Infections / Q000209:etiology; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy*; D008297:Male; D058990:Molecular Targeted Therapy; D010880:Piperidines; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011720:Pyrazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011743:Pyrimidines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016879:Salvage Therapy; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D010880:Piperidines; D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; D011743:Pyrimidines; C551803:ibrutinib; D000225:Adenine